These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

602 related articles for article (PubMed ID: 34020032)

  • 1. Intravenous immunoglobulin treatment for patients with severe COVID-19: a retrospective multicentre study.
    Liu J; Chen Y; Li R; Wu Z; Xu Q; Li Z; Annane D; Feng H; Huang S; Guo J; Zhang L; Ye X; Zhu W; Du H; Liu Y; Wang T; Chen L; Wen Z; Teboul JL; Chen D
    Clin Microbiol Infect; 2021 Oct; 27(10):1488-1493. PubMed ID: 34020032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous Immunoglobulin Therapy for Critically Ill COVID-19 Patients With Different Inflammatory Phenotypes: A Multicenter, Retrospective Study.
    Chen Y; Xie J; Wu W; Li S; Hu Y; Hu M; Li J; Yang Y; Huang T; Zheng K; Wang Y; Kang H; Huang Y; Jiang L; Zhang W; Zhong M; Sang L; Zheng X; Pan C; Zheng R; Li X; Tong Z; Qiu H; Weng L; Du B
    Front Immunol; 2021; 12():738532. PubMed ID: 35154067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes of intravenous immunoglobulin therapy in COVID-19 related acute respiratory distress syndrome: a retrospective cohort study.
    Ali HS; Elshafei MS; Saad MO; Mitwally HA; Al Wraidat M; Aroos A; Shaikh N; Ananthegowda DC; Abdelaty MA; George S; Nashwan AJ; Mohamed AS; Khatib MY
    BMC Pulm Med; 2021 Nov; 21(1):354. PubMed ID: 34743710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous immunoglobulin-based adjuvant therapy for severe COVID-19: a single-center retrospective cohort study.
    Hou X; Tian L; Zhou L; Jia X; Kong L; Xue Y; Hao H; Meng X; Zhang F; Dong X
    Virol J; 2021 May; 18(1):101. PubMed ID: 34020680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19 pneumonia in kidney transplant recipients: A promising treatment algorithm in the absence of a disease-specific drug.
    Karatas M; Tatar E; Simsek C; Yıldırım AM; Ari A; Zengel B; Uslu A
    J Med Virol; 2021 Oct; 93(10):5789-5797. PubMed ID: 34050953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperimmune anti-COVID-19 IVIG (C-IVIG) Therapy for Passive Immunization of Severe and Critically Ill COVID-19 Patients: A structured summary of a study protocol for a randomised controlled trial.
    Ali S; Luxmi S; Anjum F; Muhaymin SM; Uddin SM; Ali A; Ali MR; Tauheed S; Khan M; Bajwa M; Baig SU; Shalim E; Ahmed I; Khan AS; Quraishy S
    Trials; 2020 Nov; 21(1):905. PubMed ID: 33138867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Intravenous Immunoglobulin (Prevagen or Octagam) for the Treatment of COVID-19: Retrospective Case Series.
    Herth FJF; Sakoulas G; Haddad F
    Respiration; 2020; 99(12):1145-1153. PubMed ID: 33316806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy evaluation of intravenous immunoglobulin in non-severe patients with COVID-19: A retrospective cohort study based on propensity score matching.
    Huang C; Fei L; Li W; Xu W; Xie X; Li Q; Chen L
    Int J Infect Dis; 2021 Apr; 105():525-531. PubMed ID: 33434674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of high-dose intravenous immunoglobulin in severe and critical COVID-19: A retrospective cohort study.
    Aggarwal R; Dewan A; Pandey A; Trehan N; Majid MA
    Int Immunopharmacol; 2022 May; 106():108615. PubMed ID: 35168081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial.
    Mazeraud A; Jamme M; Mancusi RL; Latroche C; Megarbane B; Siami S; Zarka J; Moneger G; Santoli F; Argaud L; Chillet P; Muller G; Bruel C; Asfar P; Beloncle F; Reignier J; Vinsonneau C; Schimpf C; Amour J; Goulenok C; Lemaitre C; Rohaut B; Mateu P; De Rudnicki S; Mourvillier B; Declercq PL; Schwebel C; Stoclin A; Garnier M; Madeux B; Gaudry S; Bailly K; Lamer C; Aegerter P; Rieu C; Sylla K; Lucas B; Sharshar T
    Lancet Respir Med; 2022 Feb; 10(2):158-166. PubMed ID: 34774185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of early treatment with polyvalent immunoglobulin on acute respiratory distress syndrome associated with SARS-CoV-2 infections (ICAR trial): study protocol for a randomized controlled trial.
    Mazeraud A; Gonçalves B; Aegerter P; Mancusi L; Rieu C; Bozza F; Sylla K; Siami S; Sharshar T
    Trials; 2021 Feb; 22(1):170. PubMed ID: 33648563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-Dose Intravenous Immunoglobulin in Severe Coronavirus Disease 2019: A Multicenter Retrospective Study in China.
    Cao W; Liu X; Hong K; Ma Z; Zhang Y; Lin L; Han Y; Xiong Y; Liu Z; Ruan L; Li T
    Front Immunol; 2021; 12():627844. PubMed ID: 33679771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Production of hyperimmune anti-SARS-CoV-2 intravenous immunoglobulin from pooled COVID-19 convalescent plasma.
    Ali S; Uddin SM; Ali A; Anjum F; Ali R; Shalim E; Khan M; Ahmed I; M Muhaymin S; Bukhari U; Luxmi S; Khan AS; Quraishy S
    Immunotherapy; 2021 Apr; 13(5):397-407. PubMed ID: 33557591
    [No Abstract]   [Full Text] [Related]  

  • 14. Immune reactivity during COVID-19: Implications for treatment.
    Napoli C; Benincasa G; Criscuolo C; Faenza M; Liberato C; Rusciano M
    Immunol Lett; 2021 Mar; 231():28-34. PubMed ID: 33421440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Computation and COVID-19 Mortality: A Rationale for IVIg.
    Cohen IR; Efroni S; Atlan H
    Crit Rev Immunol; 2020; 40(3):195-203. PubMed ID: 33389884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consensus statement and recommendations on the treatment of COVID-19: 2021 update.
    Ko HK; Yu WK; Pan SW; Chen WC; Yang KY; Lin YT; Wang FD; Yang MH; Chen YM;
    J Chin Med Assoc; 2022 Jan; 85(1):5-17. PubMed ID: 34524227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Multisystem Inflammatory Syndrome in Children.
    McArdle AJ; Vito O; Patel H; Seaby EG; Shah P; Wilson C; Broderick C; Nijman R; Tremoulet AH; Munblit D; Ulloa-Gutierrez R; Carter MJ; De T; Hoggart C; Whittaker E; Herberg JA; Kaforou M; Cunnington AJ; Levin M;
    N Engl J Med; 2021 Jul; 385(1):11-22. PubMed ID: 34133854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The outcome of using intravenous immunoglobulin (IVIG) in critically ill COVID-19 patients': a retrospective, multi-centric cohort study.
    Salehi M; Barkhori Mehni M; Akbarian M; Fattah Ghazi S; Khajavi Rad N; Moradi Moghaddam O; Jamali Moghaddam S; Hosseinzadeh Emam M; Abtahi SH; Moradi M; Ghiasvand F
    Eur J Med Res; 2022 Feb; 27(1):18. PubMed ID: 35115056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of two Japanese ESRD cases with severe COVID-19 pneumonia.
    Abe T; Izumo T; Ueda A; Hayashi M; Ishibashi Y
    CEN Case Rep; 2021 Feb; 10(1):42-45. PubMed ID: 32715376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II/III trial of hyperimmune anti-COVID-19 intravenous immunoglobulin (C-IVIG) therapy in severe COVID-19 patients: study protocol for a randomized controlled trial.
    Ali S; Shalim E; Farhan F; Anjum F; Ali A; Uddin SM; Shahab F; Haider M; Ahmed I; Ali MR; Khan S; Rao S; Guriro K; Elahi S; Ali M; Mushtaq T; Sayeed MA; Muhaymin SM; Luxmi S; Saifullah ; Qureshi S
    Trials; 2022 Nov; 23(1):932. PubMed ID: 36348476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.